345296-38-0

Upstream product

• 99-09-2 3-nitro-aniline 
• 97-65-4 2-methylenesuccinic acid 
• 345297-66-7 ethyl 3-{(1-(3-nitrophenyl)-5-oxopyrrolidin-3-yl)carbonylamino}-3-(pyridin-3-yl)propanoate 
• 345297-65-6 1-(3-nitro-phenyl)-5-oxo-pyrrolidine-3-carboxylic acid 

Downstream Products

• 723284-68-2 2-{3-[4-(2-ethoxycarbonyl-1-pyridin-3-yl-ethylcarbamoyl)-2-oxo-pyrrolidin-1-yl]-phenylimino}-dihydro-pyrimidine-1,3-dicarboxylic acid di-tert-butyl ester 
• 791772-96-8 3-{(1-(3-{((butylamino)thioxomethyl)amino}phenyl)-5-oxopyrrolidin-3-yl)carbonylamino}-3-(3-pyridyl) propanoic acid 
• 741663-27-4 3-({1-(3-({((2-furylmethyl)amino)thioxomethyl}amino)phenyl)-5-oxopyrrolidin-3-yl}carbonylamino)-3-(3-pyridyl)propanoic acid 
• 743411-82-7 3-((1-{3-(({((4-fluorophenyl)methyl)amino}thioxo methyl)amino)phenyl}-5-oxopyrrolidin-3-yl)carbonyl amino)-3-(3-pyridyl)propanoic acid 
• 723284-69-3 3-({5-oxo-1-[3-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-phenyl]-pyrrolidine-3-carbonyl}-amino)-3-pyridin-3-yl-propionic acid ethyl ester 

Relevant academic research and scientific papers

N-Aryl-γ-lactams as integrin αvβ3 antagonists

Novel αvβ3 antagonists based on the N-aryl-γ-lactam scaffold were prepared. SAR studies led to the identification of potent antagonists for αvβ3 receptor with excellent selectivity against the structurally relat

Integrin inhibitors and their methods of use

The invention comprises novel compounds that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated diseases, in particular, diseases or conditions mediated by integrin receptors, such as a αvβ3, αvβ6, α5β1 and the like. The invention encompasses novel compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of such diseases and disorders. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.